lifelong premature ejaculation
Conditions
Interventions
The patients were divided into 2 equal groups
one group was given paroxetine and the other escitalopram single dose daily for 3 months to compare efficacy of both drugs in delaying ejaculation in patients with lifelong PE. Also, to evaluate role
Sponsors
nil
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: The patients' age was between 25-50 years with a stable and continuous marital relationship for at least one year. Condoms, topical anesthetic cream or spray before sexual intercourse were prohibited, being unable to satisfy their partners with intravaginal ejaculation latency time < 1 minute since their first sexual experience on all or nearly all vaginal penetrations with negative personal consequences on him and his partner and subsequent avoidance of sexual intimacy.
Exclusion criteria
Exclusion criteria: Men suffered from ED (IIEF score< 21), reduced sexual desire or inhibited male orgasm. Also, patients with history of urinary tract infection, mental disorders and chronic physical illnesses affecting ejaculatory function, abusers of Alcohol or drug and finally, patients who received psychotropic medications that may affect response to selective serotonin reuptake inhibitors (SSRIs) or any medical treatment for premature ejaculation in the last 6 months were also excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Majority of dopamine transporter gene polymorphisms majority were 10R/10R and 6R/10R | — |
Secondary
| Measure | Time frame |
|---|---|
| At the end of our study we found 27 patients out of 60 patients responded to paroxetin and escitalopram. Both of them were statistically highly significant in delaying ejaculation in the responders.Also, they demonstrated statistically highly significant relation with dopamine transporter gene polymorphism | — |
Countries
Africa
Contacts
Public ContactSameh Fayek
Cairo University Andrology department
Outcome results
None listed